$11.13
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Analyst Report: Intellia Therapeutics, Inc.
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Overview
52-week range
$7.31
$28
18% of range
Avg surprise (last 3)
+9.5%
Avg reaction (last 2)
+8.0%
100% positive
Latest IV / EM
75%
EM ±17.1% · $11 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.81 | $-0.92 | +12.0% | +26.4% | +2.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.92 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.99 | $-1.03 | +3.9% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-1.10 | $-1.26 | +12.7% | — | +13.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.34 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.52 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.12 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.38 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.40 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.80 | -$0.99 | +19.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | — | $14M | $14M | $17M | — | $9M | $7M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-101M | — | $-111M | $-110M | $-121M | — | $-145M | $-139M |
| Net income | $-96M | — | $-101M | $-101M | $-114M | — | $-136M | $-147M |
| EPS (diluted) | $-0.81 | — | $-0.92 | $-0.98 | $-1.10 | — | $-1.34 | $-1.52 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $135M | $155M | $193M | $156M | $127M | $189M | $120M | $131M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $466M | $528M | $582M | $496M | $551M | $640M | $711M | $757M |
| Total assets | $759M | $842M | $925M | $899M | $986M | $1.19B | $1.17B | $1.19B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $138M | $171M | $177M | $184M | $206M | $319M | $211M | $220M |
| Total equity | $621M | $671M | $748M | $715M | $780M | $872M | $963M | $971M |